using-16-18f-fluoro-17-estradiol-pet-to-visualize-estrogen-receptor

Using 16&#945;-[18F]-Fluoro-17&#946;-Estradiol PET to Visualize Estrogen Receptor &#945; Expression in Human Breast Cancer Xenografts in Female Ovariectomized Mice

To demonstrate how estrogen receptor alpha (ER&#945;) positive breast cancer xenografts may be visualized in BALB/c nude mice using ...

Olivia Newton-John Cancer Research Institute

Τhis study aimed to optimize the Zr-radiolabelling of bintrafusp alfa investigational drug product and controls, and perform the in vitro and in vivo characterization of Zr-Df-bintrafusp alfa and Zr-Df-control radioconjugates.

Radiolabelling and preclinical characterization of Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa.

Bromodomain and extraterminal (BET) proteins, a family of epigenetic regulators, have emerged as important oncology drug targets. BET proteins have not been targeted for molecular imaging of cancer. Here, we report the development of a novel molecule radiolabelled with positron emitting fluorine-18, [F]BiPET-2, and its  and preclinical evaluation in glioblastoma models.

Bromodomain and extraterminal protein-targeted probe enables tumour visualisation  using positron emission tomography.

CI-8993 is a fully human IgG1κ monoclonal antibody (mAb) that binds specifically to immune checkpoint molecule VISTA (V-domain Ig suppressor of T-cell activation). Phase I safety has been established in patients with advanced cancer (NCT02671955). To determine the pharmacokinetics and biodistribution of CI-8993 in patients, we aimed to develop Zr-labelled CI-8993 and validate PET imaging and quantitation in preclinical models prior to a planned human bioimaging trial.

Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with Zr-labelled CI-8993.

Cachexia is a complex syndrome characterized by unintentional weight loss, progressive muscle wasting and loss of appetite. Anti-Fn14 antibody (mAb 002) targets the TWEAK receptor (Fn14) in murine models of cancer cachexia and can extend the lifespan of mice by restoring the body weight of mice. Here, we investigated glucose metabolic changes in murine models of cachexia via [F]FDG PET imaging, to explore whether Fn14 plays a role in the metabolic changes that occur during cancer cachexia.

Article	Year
Radiolabelling and preclinical characterization of Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa. European journal of nuclear medicine and molecular imaging\| PubMed ID: 33608805	2021
Bromodomain and extraterminal protein-targeted probe enables tumour visualisation using positron emission tomography. Chemical communications (Cambridge, England)\| PubMed ID: 36809538	2023
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with Zr-labelled CI-8993. European journal of nuclear medicine and molecular imaging\| PubMed ID: 39060374	2024
Targeting Fn14 as a therapeutic target for cachexia reprograms the glycolytic pathway in tumour and brain in mice. European journal of nuclear medicine and molecular imaging\| PubMed ID: 39060375	2024
Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with Zr-labelled CI-8993. European journal of nuclear medicine and molecular imaging\| PubMed ID: 39186103	2024

Nhi Huynh

Biography

JoVE Journal Publications

Other Publications